Vaxcyte(NASDAQ) PCVX

Market Cap$10.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+116%
5 Year+208%
1 Year+73%
1 Month+21%
Premium Feature
Moneyball Superscore
78/100
$73.81
+30.68%
+17.33Today
After hours$70.65-$3.16 (-4.28%)
Vaxcyte last closing stock price
MetricPriceDate
Last closeUSD 73.822026-10-05
Vaxcyte stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+26.69%USD 58.272026-09-28
1 month+20.7%USD 61.162026-09-04
3 month+21.67%USD 60.672026-07-07
Year to date+59.99%USD 46.142025-12-31
1 year+73.04%USD 42.662025-10-03
3 year+50.87%USD 48.932023-10-06
5 year+208.35%USD 23.942021-10-06
Since inception+115.98%USD 26.152020-06-12

Vaxcyte Financials at a Glance

Market Cap

$10.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.06K

EPS (TTM)

-$7.71

P/E Ratio

-9.58

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$73.81

Volume

7,020.834

Open

$87.21

Previous Close

$73.82

Daily Range

$71.60 - $90.75

52-Week Range

$39.87 - $90.75

Estimated Earnings Date

N/A

PCVX: Motley Fool Moneyball Superscore

78

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Industry

Biotechnology

Employees

507

CEO

Grant E. Pickering, MBA

PCVX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-36.51%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-10.44%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$10.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

148.81M

Volume

7.02K

Avg. Volume

1.37M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Vaxcyte Performance Analysis

Vaxcyte annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vaxcyte annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.4478.7%
20232023-12-31USD -4.1420.2%
20242024-12-31USD -3.80-8.2%
20252025-12-31USD -5.6348.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.93

+1.2%

Gross Margin

N/A

N/A

Market Cap

$10.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.56

N/A

Employees

507

N/A

Net Income

-$284.30

+1.7%

EBITDA

-$296.85

+1.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$298.64

-23.9%

Total Debt

$115.45

+1.3%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$108.94

+1.4%

Short Term Debt

$6.51

+1.0%

Return on Assets

-33.03%

+1.6%

Return on Invested Capital

-26.01%

+1.0%

Free Cash Flow

-$237.05

+1.8%

Operating Cash Flow

-$232.47

+1.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About PCVX

What is the current price of Vaxcyte?

Vaxcyte is trading at $73.82 per share.

What is the 52-week range for Vaxcyte?

Over the past 52 weeks, Vaxcyte has traded between $39.87 and $90.75.

How much debt does Vaxcyte have?

As of the most recent reporting period, Vaxcyte reported total debt of $115.45M.

How much cash does Vaxcyte have on hand?

Vaxcyte reported $183.19M in cash and cash equivalents in its most recent financial results.

What is Vaxcyte’s dividend yield?

Vaxcyte does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.